Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 1:41 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1561–1584 of 3,915 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Prostate Cancer Clear all
Withdrawn No phase listed Observational

Trial of Prostate Cancer Patients Undergoing Active Surveillance With or Without MRI-Guided Management

NCT01838265
View directory record Official record
Conditions
Prostate Cancer, Prostate Adenocarcinoma
Interventions
Transrectal Ultrasound-Guided Biopsy, MRI Ultrasound Biopsy, Expanded Prostate Cancer index Composite Questionnaire, Short-Form 12 of Health Related Quality of Life Questionnaire, Memorial Anxiety Scale for Prostate Cancer, Plasma/Serum Sample for biomarkers, Urine Sample for Biomarkers, Blood Tests for Blood Urea Nitrogen and Creatinine, Blood Test for Serum PSA
Procedure · Behavioral
Lead sponsor
University of Miami
Other
Eligibility
35 Years to 75 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 8, 2014 · Synced Nov 3, 2026, 1:41 AM EST
Terminated No phase listed Observational

Registry to Evaluate Long-Term Outcomes in Patients Who Undergo 68-Ga-PSMA-11 PET/CT Imaging Evaluations

NCT06655064
View directory record Official record
Conditions
Prostate Cancer (Adenocarcinoma)
Interventions
None- Observational
Other
Lead sponsor
Telix Pharmaceuticals (Innovations) Pty Limited
Industry
Eligibility
21 Years and older · Male only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
9
States / cities
Fresno, California • Grand Junction, Colorado • Meridian, Idaho + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2025 · Synced Nov 3, 2026, 1:41 AM EST
Withdrawn Phase 2 Interventional

Botulinum Toxin Injection With Prostate Brachytherapy

NCT00681148
View directory record Official record
Conditions
Prostate Cancer, Lower Urinary Tract Symptoms, Radioactive Seed Implantation
Interventions
Botox injection, Saline injection
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2012
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 21, 2013 · Synced Nov 3, 2026, 1:41 AM EST
Recruiting Not applicable Interventional

Study to Assess the Feasibility of Stopping Prostate Cancer Treatment Early in Elderly Patients

NCT06824818
View directory record Official record
Conditions
Elderly, Prostate Cancer
Interventions
LHRH Agonist Therapy Discontinuation
Behavioral
Lead sponsor
University of Chicago
Other
Eligibility
70 Years and older · Male only
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Nov 3, 2026, 1:41 AM EST
Recruiting Phase 2 Interventional

Measuring Circulating Tumor Deoxyribonucleic Acid Tumor Fraction to Guide Early 177Lu-PSMA-617 Treatment Discontinuation in Patients With Metastatic Castration-Resistant Prostate Cancer, DYNAMO Trial

NCT07698535
View directory record Official record
Conditions
Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Lutetium Lu 177 Vipivotide Tetraxetan, Cell-free Circulating Tumor DNA Assay, Computed Tomography, Docetaxel, PSMA PET Scan, Single Photon Tomography and Computed Tomography Scan, Biospecimen Collection
Drug · Procedure
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Male only
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Nov 3, 2026, 1:41 AM EST
Completed Phase 2 Interventional

Psychostimulants for Fatigue in Prostate Cancer

NCT00138138
View directory record Official record
Conditions
Fatigue, Prostate Cancer
Interventions
Ritalin
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
40 Years to 90 Years · Male only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 10, 2007 · Synced Nov 3, 2026, 1:41 AM EST
Recruiting Phase 2 Interventional

Optimal PSA Triggered Individual Management of Androgen Sensitive Prostate Cancer

NCT07216248
View directory record Official record
Conditions
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Interventions
relugolix + ARPI., Intermittent- Relugolix or androgen deprivation therapy (ADT) + ARPI, relugolix or androgen deprivation therapy (ADT) + ARPI
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older · Male only
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Nov 3, 2026, 1:41 AM EST
Terminated No phase listed Observational Accepts healthy volunteers

ExoDx Prostate Evaluation in Prior Negative Prostate Biopsy Setting

NCT04357717
View directory record Official record
Conditions
Prostate Cancer
Interventions
ExoDx Prostate
Diagnostic Test
Lead sponsor
Exosome Diagnostics, Inc.
Industry
Eligibility
50 Years and older · Male only
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
2
States / cities
Baltimore, Maryland • Voorhees Township, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 31, 2022 · Synced Nov 3, 2026, 1:41 AM EST
Recruiting Not applicable Interventional

Transrectal Ultrasound Robot-Assisted Prostate Biopsy

NCT02871726
View directory record Official record
Conditions
Prostate Cancer
Interventions
TRUS-Robot, TRUS biopsy
Device · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
45 Years to 75 Years · Male only
Enrollment
483 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Nov 3, 2026, 1:41 AM EST
Completed Not applicable Interventional

Outcomes of Triaged Family Care in Advanced Cancer

NCT00709176
View directory record Official record
Conditions
Advanced Cancer
Interventions
Brief FOCUS Program, Extensive FOCUS Program
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
484 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
5
States / cities
Ann Arbor, Michigan • Detroit, Michigan • Southfield, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 11, 2014 · Synced Nov 3, 2026, 1:41 AM EST
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Veteran Peer Navigators to Promote Shared Decision Making for PSA Screening

NCT06549036
View directory record Official record
Conditions
Prostate Cancer
Interventions
Veteran Peer Decision Coaching Session for PSA Screening
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
40 Years to 69 Years · Male only
Enrollment
228 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2027 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Nov 3, 2026, 1:41 AM EST
Completed Phase 2 Interventional Results available

Evaluating E7389 in Patients With Hormone Refractory Prostate Cancer With Advanced and/or Metastatic Disease Stratified by Prior Chemotherapy

NCT00278993
View directory record Official record
Conditions
Prostate Cancer
Interventions
E7389
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
18
States / cities
Denver, Colorado • Melbourne, Florida • Ocala, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2014 · Synced Nov 3, 2026, 1:41 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Men's Prostate Awareness Church Training

NCT02131779
View directory record Official record
Conditions
Prostate Cancer
Interventions
Men's Workshops, Co-Educational Workshops
Behavioral
Lead sponsor
University of Maryland, College Park
Other
Eligibility
40 Years to 69 Years
Enrollment
536 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2018
U.S. locations
1
States / cities
College Park, Maryland
Source: ClinicalTrials.gov public record
Updated May 23, 2022 · Synced Nov 3, 2026, 1:41 AM EST
Recruiting Not applicable Interventional

Reduce HEAT: A Randomized Trial of Wearable Thermal Devices for ADT-Induced Hot Flashes

NCT07729150
View directory record Official record
Conditions
Prostate Cancer, Hot Flashes, Vasomotor Symptoms
Interventions
Embr Wave
Device
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Nov 3, 2026, 1:41 AM EST
Terminated Phase 2 Interventional

YM598 Added to Mitoxantrone/Prednisone to Control Pain in Metastatic Prostate Cancer Patients No Longer Responding to Hormone Therapy

NCT00048659
View directory record Official record
Conditions
Hormone-Refractory Prostate Cancer, Prostatic Neoplasms
Interventions
YM598
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2004
U.S. locations
14
States / cities
Anchorage, Alaska • San Bernardino, California • Torrance, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2012 · Synced Nov 3, 2026, 1:41 AM EST
Completed Phase 1 Interventional

Dendreon Lymph Node Biopsy in Metastatic Castrate-Resistant Prostate Cancer

NCT02036918
View directory record Official record
Conditions
Prostate Cancer
Interventions
Sipuleucel-T, Lymph Node Biopsy
Drug · Procedure
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 31, 2020 · Synced Nov 3, 2026, 1:41 AM EST
Completed Phase 2 Interventional Results available

Axitinib Before Surgery in Treating Patients With High-Risk Prostate Cancer

NCT01385059
View directory record Official record
Conditions
Stage III Prostate Cancer, Stage IV Prostate Cancer
Interventions
axitinib, therapeutic conventional surgery, enzyme-linked immunosorbent assay, laboratory biomarker analysis
Drug · Procedure · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Mar 7, 2023 · Synced Nov 3, 2026, 1:41 AM EST
Withdrawn No phase listed Observational

Imaging of Residual Tumor During Prostatectomy

NCT01173146
View directory record Official record
Conditions
Prostate Cancer
Interventions
Not listed
Lead sponsor
Spectros Corporation
Industry
Eligibility
Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 25, 2016 · Synced Nov 3, 2026, 1:41 AM EST
Not listed Early Phase 1 Interventional

Gadoxetate Sodium Enhanced MRI as a Biomarker for Aggressive Prostate Cancer

NCT03960788
View directory record Official record
Conditions
Cancer of the Prostate, Castration-resistant Prostate Cancer
Interventions
Gadoxetate Sodium
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 23, 2019 · Synced Nov 3, 2026, 1:41 AM EST
Completed No phase listed Observational

Palladium-103 Seed Implant and Single Daily Dosing of Uroxatral Vs. Twice Daily Dosing of Flomax- A 3 Month Retrospective Efficacy Analysis

NCT00264017
View directory record Official record
Conditions
Prostate Cancer Patients Undergoing External Radiation and Seed Implantation
Interventions
Not listed
Lead sponsor
Dattoli Cancer Center and Brachytherapy Research Institute
Other
Eligibility
45 Years to 80 Years · Male only
Enrollment
60 participants
Timeline
2005
U.S. locations
1
States / cities
Sarasota, Florida
Source: ClinicalTrials.gov public record
Updated Dec 12, 2005 · Synced Nov 3, 2026, 1:41 AM EST
Terminated Phase 2 Interventional Results available

Genistein in Treating Patients With Prostate Cancer

NCT01126879
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage I Prostate Cancer, Stage II Prostate Cancer, Stage III Prostate Cancer
Interventions
genistein, placebo, therapeutic conventional surgery
Dietary Supplement · Other · Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 10, 2019 · Synced Nov 3, 2026, 1:41 AM EST
Active, not recruiting Phase 1 Interventional

A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors

NCT06238479
View directory record Official record
Conditions
Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm, Triple Negative Breast Cancer, Non-small Cell Lung Cancer, Esophageal Cancer, Pancreatic Cancer, Ovarian Cancer, Cervical Cancer, Head and Neck Squamous Cell Carcinoma, Prostate Cancer, Renal Pelvis Cancer, Bladder Cancer
Interventions
LY4101174
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
490 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
9
States / cities
Orlando, Florida • Atlanta, Georgia • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Nov 3, 2026, 1:41 AM EST
Not yet recruiting No phase listed Observational

LTFU for All Cell and Gene Therapy Studies

NCT06194461
View directory record Official record
Conditions
Hepatocellular Carcinoma, Prostate Cancer
Interventions
AZD5851, AZD0754
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2041
U.S. locations
18
States / cities
Phoenix, Arizona • Duarte, California • Orange, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2025 · Synced Nov 3, 2026, 1:41 AM EST
Completed Phase 4 Interventional Results available

Deep Versus Moderate Neuromuscular Blockade During Laparoscopic Surgery

NCT02812186
View directory record Official record
Conditions
Cholecystitis, Endometriosis, Bowel Obstruction, Fibroids, Prostate Cancer, Chronic Kidney Disease, Uterine Prolapse
Interventions
Deep to Moderate NMB, Moderate to Deep NMB, Rocuronium
Procedure · Drug
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Apr 8, 2020 · Synced Nov 3, 2026, 1:41 AM EST